• COVID-19
  • Biosimilars
  • Cataract Therapeutics
  • DME
  • Gene Therapy
  • Workplace
  • Ptosis
  • Optic Relief
  • Imaging
  • Geographic Atrophy
  • AMD
  • Presbyopia
  • Ocular Surface Disease
  • Practice Management
  • Pediatrics
  • Surgery
  • Therapeutics
  • Optometry
  • Retina
  • Cataract
  • Pharmacy
  • IOL
  • Dry Eye
  • Understanding Antibiotic Resistance
  • Refractive
  • Cornea
  • Glaucoma
  • OCT
  • Ocular Allergy
  • Clinical Diagnosis
  • Technology

WaveLight attains 20% of U.S. refractive laser sales in 1 year


New Orleans-WaveLight Inc. announced that during the last 12 months, its Allegretto Wave laser achieved a 20% share of all new refractive laser sales in the United States.

"We consider our success in the U.S. market to be our greatest accomplishment to date," said Max Reindl, chief executive officer of WaveLight Laser Technologie AG. "Ophthalmologists and patients alike benefit from the Allegretto Wave's shorter treatment times, safety features, and unique ablation profile designed to minimize the induction of spherical aberrations during surgery. Strong demand for the Allegretto Wave validates our commitment to develop and introduce the most innovative technology in the marketplace."

In addition to acquiring a considerable presence within ophthalmology, WaveLight recently announced that its revenues have increased 30% for the fiscal year ending July 31, 2004. WaveLight attributes much of its financial performance to refractive laser sales.

Related Videos
EyeCon 2024: Peter J. McDonnell, MD, marvels on mentoring, modern technology, and ophthalmology’s future
Lorraine Provencher, MD, presenting slides
Katherine Talcott, MD, presenting slides
Katherine Talcott, MD, presenting slides
© 2024 MJH Life Sciences

All rights reserved.